Abstract: AZD5363 (Capivasertib) is a potent, oral, ATP-competitive pan-AKT inhibitor that has recently emerged as a significant targeted therapy in oncology. While the specified research direction for this review is Non-Hodgkin Lymphoma (NHL), the provided literature exclusively details the compound's efficacy, mechanism, and clinical development in solid tumors, particularly hormone receptor-positive (HR+)/HER2-negative breast cancer, gynecological malignancies, prostate cancer, and hepatocellular carcinoma. Consequently, this review synthesizes the available data on AZD5363's pharmacological profile across these solid tumors. AZD5363 exerts its anti-tumor effects by binding to the ATP-binding site of AKT isoforms (AKT1, AKT2, and AKT3), thereby disrupting downstream signaling pathways involved in cell proliferation, glucose metabolism, and apoptosis. Recently approved by the FDA for HR+/HER2- advanced breast cancer harboring PIK3CA/AKT1/PTEN alterations, AZD5363 demonstrates significant clinical benefit when combined with fulvestrant. However, its clinical utility is limited by on-target toxicities such as hyperglycemia and rash, as well as a strong dependence on specific biomarker alterations for optimal efficacy. Future perspectives emphasize rational combination strategies and rigorous biomarker-driven patient selection.
1. Introduction
AZD5363, also known as capivasertib, is a novel, orally bioavailable pan-AKT kinase inhibitor [1][2]. The PI3K/AKT/mTOR signaling pathway plays a central role in cell proliferation, survival, and metabolism, and its hyperactivation is frequently implicated in oncogenesis and treatment resistance across various malignancies [1]. In November 2023, AZD5363 received FDA approval for use in combination with the estrogen receptor antagonist fulvestrant to treat adult patients with HR-positive/HER2-negative locally advanced or metastatic breast cancer harboring one or more PIK3CA, AKT1, or PTEN alterations [2][3].
Note on Research Direction: The target research direction for this review is Non-Hodgkin Lymphoma (NHL). However, the provided literature contains no preclinical or clinical data regarding the use of AZD5363 in NHL. Therefore, this review comprehensively analyzes the pharmacological and molecular profile of AZD5363 based strictly on the provided data, which predominantly focuses on breast cancer, gynecological cancers, prostate cancer, hepatocellular carcinoma, and meningioma.
2. Pharmacological Activity
AZD5363 has demonstrated significant pharmacological activity across multiple solid tumors, both as a monotherapy and in combination regimens:
Breast Cancer: AZD5363 has shown profound efficacy in HR+/HER2- metastatic breast cancer. In the phase III CAPItello-291 trial, the addition of AZD5363 to fulvestrant significantly improved median progression-free survival (PFS) from 3.1 months to 7.3 months in patients with PIK3CA/AKT1/PTEN-altered tumors [4]. The phase II FAKTION trial similarly demonstrated improved PFS (10.3 vs. 4.8 months) and overall survival (OS) (29.3 vs. 23.4 months) for the combination [4][5]. It has also shown activity in triple-negative breast cancer (TNBC) when combined with paclitaxel in the PAKT trial [6].
Prostate Cancer: In metastatic castration-resistant prostate cancer (mCRPC), AZD5363 was evaluated in the phase II ProCAID trial in combination with docetaxel and prednisolone. While it did not extend composite PFS, it significantly increased OS (31.15 vs. 20.27 months) [7].
Gynecological Cancers: In endometrial, ovarian, and cervical cancers, AZD5363 monotherapy achieved target modulation but showed limited clinical efficacy, with objective response rates (ORR) falling below predefined thresholds (e.g., 8% in gynecologic cohorts) [3].
Hepatocellular Carcinoma (HCC): Preclinical studies show AZD5363 suppresses the proliferation of human HCC cell lines (HepG2 and Huh-7) in a dose- and time-dependent manner [8].
Meningioma: AZD5363 has demonstrated durable control in metastatic AKT1-mutant WHO Grade 1 meningioma [9].
3. Molecular Mechanism of Action
AZD5363 is a potent ATP-competitive inhibitor that binds directly to the ATP-binding site of the AKT kinase [1]. It effectively inhibits all three AKT isoforms (AKT1, AKT2, and AKT3), thereby restricting oncogenic signaling downstream of PI3K and PTEN [2].
At the molecular level, AZD5363 reduces the phosphorylation of downstream effectors, including glycogen synthase kinase 3 beta (GSK3β) and ribosomal protein S6, which disrupts glucose metabolism and protein synthesis [3]. Furthermore, AZD5363 induces the nuclear localization of forkhead box O1 (FOXO1) and p53, reduces the phosphorylation of the BCL2-associated agonist of cell death (BAD), induces cell-cycle arrest, and promotes apoptosis [3][8].
In the context of hormone receptor-positive cancers, AKT hyperactivation can cause ligand-independent phosphorylation of the estrogen receptor (ER), leading to endocrine therapy resistance. AZD5363 suppresses ER-mediated transcription by reducing the recruitment of ER and CREB-binding protein coactivators to estrogen response elements, providing a strong mechanistic rationale for combining it with anti-estrogen therapies like fulvestrant [1].
4. Structure-Activity Relationship (SAR)
While exhaustive structural modification data is not detailed in the provided literature, the SAR profile of AZD5363 is defined by its classification as an ATP-competitive inhibitor, distinguishing it from allosteric AKT inhibitors (such as MK-2206) [11]. AZD5363 exhibits balanced, nanomolar potency against all three AKT isoforms. Specifically, it demonstrates an IC50 of 3 nmol/L against AKT1, 9 nmol/L against AKT2, and 3 nmol/L against AKT3 [10]. This balanced isoform selectivity enables the effective inhibition of downstream signaling even in the presence of diverse genomic alterations across the PI3K/AKT/PTEN pathway [10].
5. Current Limitations
Despite its clinical success, the use of AZD5363 is constrained by several limitations:
Toxicity Profile: Because AZD5363 inhibits physiologic PI3K/AKT pathway signaling, it induces significant on-target, off-tumor toxicities [2]. The most common adverse events include severe diarrhea, cutaneous adverse reactions (such as maculopapular rash, occurring in up to 38% of patients), and hyperglycemia [2]. Hyperglycemia occurs because AKT is essential for insulin-mediated glucose uptake via GLUT4 vesicle fusion; inhibiting AKT induces insulin resistance and gluconeogenesis [2].
Biomarker Dependence: The efficacy of AZD5363 is highly dependent on the presence of specific genetic alterations. In the CAPItello-291 trial, the survival benefit was primarily driven by the PIK3CA/AKT1/PTEN-altered cohort. Patients without these alterations derived limited benefit (HR 0.79), meaning that unselected use could expose patients to toxicity without guaranteed efficacy [12].
Limited Monotherapy Efficacy: As a single agent, AZD5363 has shown limited efficacy in heavily pretreated solid tumors, necessitating its use in combination regimens to achieve meaningful clinical outcomes [3].
6. Future Perspectives
The future development of AZD5363 relies heavily on rational combination strategies and precision medicine. Ongoing trials are evaluating AZD5363 in combination with CDK4/6 inhibitors (e.g., palbociclib in the CAPItello-292 trial) and PARP inhibitors (e.g., olaparib) to overcome resistance mechanisms and enhance efficacy [3][12].
Furthermore, the integration of routine next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) or tissue biopsies will be critical to accurately identify patients with PIK3CA/AKT1/PTEN alterations who are most likely to benefit from AZD5363 [10]. While current data establishes its role in solid tumors, future preclinical and clinical investigations are required to determine if the mechanistic rationale of AKT inhibition with AZD5363 can be successfully translated to hematological malignancies, including Non-Hodgkin Lymphoma.
